Phibro Animal Health Corporation's (PAHC) sustained growth in the Animal Health business is backed by robust sales of vaccines and Medicated Feed Additives ("MFAs"). The company's focus on advancing vaccine technologies, along with the new vaccine production unit, instills optimism. Strong sales growth outside the United States seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro's operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 71.5% compared with the indu ...